Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00038675 · OUTCOME

Duration of Response

Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate · Source last updated 2022-01-04

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
Months
Interval / dispersion
Full Range
Time frame
From response evaluation (first evaluation following 2 months therapy) to disease progression or death or until disease progression whichever occurs first, up to 12 years and 5 months

What was measured

Time from response to disease progression, measuring length of the response in those participants who responded.

Groups in this outcome

Imatinib Mesylate

Imatinib mesylate 400 mg orally daily, HES participants start with 100 mg orally daily.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Imatinib Mesylate125

Reported measurements

Source class 1
Values in Months · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Imatinib Mesylate68Not reported33.3149Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        33.3
        upper Limit
        149
        value
        68
denoms
  1. counts
    1. group Id
      OG000
      value
      125
    units
    Participants
description
Time from response to disease progression, measuring length of the response in those participants who responded.
dispersion Type
Full Range
groups
  1. description
    Imatinib mesylate 400 mg orally daily, HES participants start with 100 mg orally daily.
    id
    OG000
    title
    Imatinib Mesylate
param Type
MEDIAN
reporting Status
POSTED
time Frame
From response evaluation (first evaluation following 2 months therapy) to disease progression or death or until disease progression whichever occurs first, up to 12 years and 5 months
title
Duration of Response
type
SECONDARY
unit Of Measure
Months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice